A Double-Blind, Placebo-Controlled, Crossover Study of Osmotic Release Oral System Methylphenidate in Adults With ADHD With Assessment of Oppositional and Emotional Dimensions of the Disorder
The DOI matches its Crossref record.
Abstract
BACKGROUND: The realization that attention-deficit/hyperactivity disorder (ADHD) often persists into adulthood has led to increased frequency of diagnosis and treatment in adults. Osmotic release oral system (OROS) methylpheni-date is a long-acting stimulant demonstrated to be effective in the treatment of children and adolescents with ADHD. METHOD: Forty-seven adults entered and 41 completed this double-blind, placebo-controlled, crossover trial of OROS methylphenidate. Each double-blind arm lasted 4 weeks; data were collected from August 2004 through December 2005. Subjects met both DSM-IV-TR and Utah Criteria for ADHD in adults. Outcome measures included the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS), the adult ADHD-Rating Scale (ADHD-RS), and the Clinical Global Impressions-Improvement scale (CGI-I). At baseline, subjects were categorized as having significant emotional symptoms with the WRAADDS and/or significant oppositional-defiant symptoms using a self-report scale assessing the DSM-IV criteria for oppositional defiant disorder. RESULTS: 17% of the sample (N = 8) had ADHD alone, 38% (N = 18) had ADHD plus significant emotional symptoms, and 40% (N = 19) had ADHD with both significant emotional and oppositional symptoms. At a mean +/- SD dose of 64.0 +/- 23.3 (0.75 mg/kg), OROS methylphenidate proved superior to placebo for all clinical measures: total WRAADDS score decrease of 42% versus 13%, respectively, p < .001 and total ADHD-RS score decrease of 41% versus 14%, respectively, p = .003, plus the subscales addressing inattention, hyperactivity/ impulsivity, and emotional dysregulation. CONCLUSIONS: OROS methylphenidate proved effective in treating adult ADHD. ADHD alone was relatively uncommon. Over 80% of our patients had ADHD with a combination of emotional and/or oppositional symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This has been supported to some extent by recent clinic-based studies reporting impairing emotion dysregulation in between 34-70% of adults with ADHD, although population based studies are needed (69-73)–Table 1.”
From Emotion Dysregulation in Attention Deficit Hyperactivity Disorder (2014) · cites this paper as [72]
In the citing paper
“The paucity of empirical support for stimulant effects on emotional lability stands in stark contrast with the numerous, randomized clinical trials demonstrating stimulant’s short term efficacy on the diagnostic symptoms of ADHD [32, 33].”
From Using Stimulants to Treat ADHD-Related Emotional Lability (2014) · cites this paper as [33]
In the citing paper
“Recent trials in ADHD patients indicate that besides ADHD symptoms, mood instability improves with both stimulant treatment and atomoxetine [234,235].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [234]
In the citing paper
“Symptoms such as demoralisation and low self-esteem following a life with ADHD, and mood instability, improve with stimulant treatment alone [234].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [234]
Citations
Cites
Still being checked.
Cited by
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Symptoms such as demoralisation and low self-esteem following a life with ADHD, and mood instability, improve with stimulant treatment alone [234].”
Faraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387
Maternal emotion and cognitive control capacities and parenting: A conceptual framework
Crandall, A., Deater-Deckard, K., & Riley, A. W. (2015) · Developmental Review · doi:10.1016/j.dr.2015.01.004 · Cited by 371
Adult attention-deficit hyperactivity disorder: key conceptual issues
Asherson, P., Buitelaar, J., Faraone, S. V., & Rohde, L. A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30032-3 · Cited by 347
Metadata
- Authors
- Reimherr, F. W., Williams, E. D., Strong, R. E., Mestas, R., Soni, P., & Marchant, B. K.
- Affiliations
- University of Utah (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-01-15
- Volume
- 68
- Issue
- 01
- Pages
- 93-101
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2025163293
- Cited by
- 180
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 7 · 2017: 11 · 2016: 9 · 2015: 12 · 2014: 15 · 2013: 11 · 2012: 16
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- adult ADHD, OROS methylphenidate, long-acting stimulants, oppositional defiant disorder, emotional dysregulation, emotional symptoms, inattention, hyperactivity/impulsivity, ADHD Rating Scale, treatment efficacy
- MeSH terms
- Administration, Oral, Adult, Affective Symptoms, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Methylphenidate, Middle Aged, Osmosis, Treatment Outcome, Cross-Over Studies, Attention Deficit and Disruptive Behavior Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Blind, Placebo-Controlled, Crossover Study of Osmotic Release Oral System Methylphenidate in Adults With ADHD With Assessment of Oppositional and Emotional Dimensions of the Disorder. https://app.cochat.ai/papers/10.4088/jcp.v68n0113
- The paper
- Reimherr, F. W., Williams, E. D., Strong, R. E., Mestas, R., Soni, P., & Marchant, B. K. (2007). A Double-Blind, Placebo-Controlled, Crossover Study of Osmotic Release Oral System Methylphenidate in Adults With ADHD With Assessment of Oppositional and Emotional Dimensions of the Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v68n0113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.